Influenza B Infections - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Influenza B Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Influenza B Infections - Pipeline Review, H2 2014', provides an overview of the Influenza B Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza B Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Influenza B Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Influenza B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Influenza B Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Influenza B Infections Overview 7
Therapeutics Development 8
Pipeline Products for Influenza B Infections - Overview 8
Pipeline Products for Influenza B Infections - Comparative Analysis 9
Influenza B Infections - Therapeutics under Development by Companies 10
Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 11
Influenza B Infections - Pipeline Products Glance 12
Early Stage Products 12
Influenza B Infections - Products under Development by Companies 13
Influenza B Infections - Products under Investigation by Universities/Institutes 14
Influenza B Infections - Companies Involved in Therapeutics Development 15
Autoimmune Technologies, LLC 15
Takeda Pharmaceutical Company Limited 16
Crucell N.V. 17
Chimerix, Inc. 18
REPLICor Inc. 19
AltraVax Inc. 20
ContraFect Corporation 21
Humabs BioMed SA 22
Influenza B Infections - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
REP-9 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Influenza VLP Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Flufirvitide-3 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CF-403 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CR-8071 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CR-8033 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CR-9114 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Influenza B - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Monoclonal Antibody for Influenza B Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AL-18 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
influenza B vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Influenza B Infections - Recent Pipeline Updates 43
Influenza B Infections - Dormant Projects 44
Influenza B Infections - Product Development Milestones 45
Featured News & Press Releases 45
Oct 18, 2012: Sanofi Pasteur's sBLA For New Four-Strain Influenza Vaccine Accepted For Review By FDA 45
Aug 22, 2012: Biota Announces Inavir Achieves Primary Endpoint in Phase III Prevention Study 46
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 46
Oct 26, 2000: Hexavalent pediatric vaccines licensed in EU 47
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Influenza B Infections, H2 2014 8
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Influenza B Infections - Pipeline by Autoimmune Technologies, LLC, H2 2014 15
Influenza B Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 16
Influenza B Infections - Pipeline by Crucell N.V., H2 2014 17
Influenza B Infections - Pipeline by Chimerix, Inc., H2 2014 18
Influenza B Infections - Pipeline by REPLICor Inc., H2 2014 19
Influenza B Infections - Pipeline by AltraVax Inc., H2 2014 20
Influenza B Infections - Pipeline by ContraFect Corporation, H2 2014 21
Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Influenza B Infections Therapeutics - Recent Pipeline Updates, H2 2014 43
Influenza B Infections - Dormant Projects, H2 2014 44